Prenetics Global (PRE) Stock Price, News & Analysis

Company Overview

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that develops and delivers health insights through its proprietary technology platforms. Founded in 2014 and headquartered in Hong Kong, Prenetics combines genomics, data analytics and telehealth to offer personalized health solutions spanning preventive care, sports performance and pharmaceutical development. The company’s business model integrates laboratory services with digital reporting tools, enabling clients to access actionable information about their genetic predispositions, nutritional needs and disease risks.

The company’s core products include at-home saliva and blood sample collection kits for genetic and diagnostic testing, complemented by an online portal and mobile app that provide users with real-time results, lifestyle recommendations and expert consultations. Prenetics’ services cover a broad spectrum of tests such as whole-genome sequencing, pharmacogenomics, microbiome analysis and COVID-19 screening. In addition, the firm offers specialized testing packages for elite athletes, corporate wellness programs and fertility clinics, tailoring test panels to the unique requirements of each segment.

Prenetics has established an international footprint across Asia, Europe, the Middle East and North America, operating clinical laboratories in Hong Kong, London and Los Angeles. The company partners with healthcare providers, research institutions and sports organizations to expand its distribution network and accelerate the adoption of precision medicine. Through strategic collaborations with pharmaceutical companies, Prenetics also supports drug development efforts by providing companion diagnostics and real-world evidence derived from its genomic database.

Led by co-founder and Chief Executive Officer Manny Miranda, Prenetics’ leadership team brings together expertise in biotechnology, software engineering and regulatory affairs. The company’s governance framework emphasizes quality management and compliance with international standards, including ISO accreditation for laboratory operations. By combining scientific innovation with scalable digital infrastructure, Prenetics aims to drive down the cost of genetic testing and empower individuals to make informed health decisions.

Key Stats

• Today's Range: $7.94 to $8.41
• 50-Day Range: $5.20 to $11.23
• 52-Week Range: $3.09 to $11.99
• Volume: 40,102 shs
• Average Volume: 22,613 shs
• Market Capitalization: $98.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Buy

Prenetics Global Stock Analysis - MarketRank™

Prenetics Global scored higher than 28% of companies evaluated by MarketBeat, and ranked 728th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

Prenetics Global has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Prenetics Global has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Prenetics Global are expected to grow in the coming year, from ($3.30) to ($2.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Prenetics Global is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Prenetics Global is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Prenetics Global has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.38% of the float of Prenetics Global has been sold short.

Short Interest Ratio / Days to Cover

Prenetics Global has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Prenetics Global has recently decreased by 4.64%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Prenetics Global does not currently pay a dividend.

Dividend Growth

Prenetics Global does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.38% of the float of Prenetics Global has been sold short.

Short Interest Ratio / Days to Cover

Prenetics Global has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Prenetics Global has recently decreased by 4.64%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Prenetics Global this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Prenetics Global insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 25.01% of the stock of Prenetics Global is held by institutions.

PRE Stock Analysis - Frequently Asked Questions

How have PRE shares performed this year?

Prenetics Global's stock was trading at $5.80 at the start of the year. Since then, PRE shares have increased by 39.8% and is now trading at $8.11.

How were Prenetics Global's earnings last quarter?

Prenetics Global Limited (NASDAQ:PRE) issued its quarterly earnings data on Thursday, June, 12th. The company reported ($0.80) earnings per share (EPS) for the quarter. The firm earned $17.31 million during the quarter. Prenetics Global had a negative net margin of 115.91% and a negative trailing twelve-month return on equity of 28.07%.

When did Prenetics Global's stock split?

Prenetics Global's stock reverse split on the morning of Tuesday, November 14th 2023.The 1-15 reverse split was announced on Wednesday, November 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, November 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Prenetics Global?

Shares of PRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Prenetics Global own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Prenetics Global investors own include Arista Networks (ANET), Adobe (ADBE), Broadcom (AVGO), NVIDIA (NVDA), Intuit (INTU), Arch Capital Group (ACGL) and Celestica (CLS).

Company Calendar

• Last Earnings: 6/12/2025
• Today: 7/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:PRE
• CIK: 1876431
• Web: www.prenetics.com
• Phone: 852-2210-9588
• Fax: N/A
• Employees: 1
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Prenetics Global: $9.00
• High Price Target: $9.00
• Low Price Target: $9.00
• Potential Upside/Downside: +11.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.99)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$46.30 million
• Net Margins: -115.91%
• Pretax Margin: -143.22%
• Return on Equity: -28.07%
• Return on Assets: -22.27%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.07
• Quick Ratio: 1.89

Sales & Book Value

• Annual Sales: $30.62 million
• Price / Sales: 3.22
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $14.04 per share
• Price / Book: 0.57

Miscellaneous

• Outstanding Shares: 12,200,000
• Free Float: N/A
• Market Cap: $98.45 million
• Optionable: Not Optionable
• Beta: 0.15